The controlled-substance number: the certifying-clinician access point

It is a state registration issued by the New Mexico Board of Pharmacy, separate from a federal DEA number. The published rule requires the New Mexico number, not the federal one (7.35.3.9 (D)(2), p. 3).

• Created by the New Mexico Controlled Substances Act (NMSA 1978, Sections 30-31-1 through 30-31-42) and Board of Pharmacy rule 16.19.20 NMAC.
• Issued by the New Mexico Board of Pharmacy, within the Regulation and Licensing Department.
• Who may hold it: only enumerated prescribing and administering license types. The Act’s definition (Section 30-31-2(P)) lists physician, doctor of oriental medicine, dentist, physician assistant, certified nurse practitioner, clinical nurse specialist, certified nurse-midwife, prescribing psychologist, veterinarian, pharmacist and pharmacist clinician, and others “licensed or certified to prescribe and administer drugs.”
• What it authorizes: to administer, prescribe, or dispense controlled substances in New Mexico, within a “valid practitioner-patient relationship” as defined by the holder’s own licensing board.
• Versus a DEA number: separate registrations, and the order between them is in dispute. Board of Pharmacy rule 16.19.20.14(B) NMAC lists a current DEA registration among the application materials, while the practice described on the record is that the state number comes first and the DEA number follows. A board member said on July 17, in a transcript that carries no speaker labels: “there are people that have the state controlled substance that don’t have any DEA license.” The department said it is checking the point with the Board of Pharmacy. Both registrations precede enrollment in the state Prescription Monitoring Program.

Sources: 16.19.20 NMAC; NMSA 30-31-2; New Mexico Board of Pharmacy practitioner application; July 17 board transcript, unofficial and not speaker-attributed. The relationship between the state number and a DEA registration is the one point in this section that is not settled; the rest is confirmed against the primary source.

Under New Mexico law, diagnosis and prescribing authority are separate. A licensed clinical social worker or a licensed psychologist can diagnose PTSD and depression without holding any controlled-substance number.

Social workers. The Social Work Practice Act (Section 61-31-6) defines clinical social work practice to include “the diagnosis, treatment and prevention of psychosocial dysfunction, disability or impairment, including but not limited to emotional and mental disorders,” and defines clinical social work services as “assessment, diagnosis and treatment, including psychotherapy and counseling.” The section says nothing about a controlled-substance registration or prescribing authority. LCSWs have no prescriptive authority in New Mexico.

Psychologists. An ordinary licensed psychologist may diagnose and treat mental disorders but cannot prescribe. New Mexico separately created a “prescribing psychologist” designation and a “conditional prescription certificate”; that subset may “administer and prescribe psychotropic medication” and “must comply with all other state and federal laws regulating the administering and prescribing of controlled substances.” A psychologist without that certificate can diagnose but cannot hold a controlled-substance number as a prescriber.

The effect. Diagnosing a qualifying condition sits within the scope of several non-prescribing license types; holding a controlled-substance number is limited to the prescribing license types in section 1. So the requirement narrows the certifying pool from “those who can diagnose the condition” to “the subset who can also prescribe controlled substances.” The department settled this for the published rule: it declined to accept a non-prescribing provider as a certifying clinician, and 7.35.3.9 (D)(2) requires the number of every applicant for that role. The rule is proposed, not final, and the question can be raised again at the August 28 hearing.

Verified. Sources: NMSA 61-31-6; NMSA 61-9-17.2.

Entry is not based on a diagnosis alone. The Act sets a two-part test: a diagnosed qualifying condition and a separate clinician judgment of medical appropriateness. Its definition of “clinician” names no license type and requires no controlled-substance number.

The program was created by Senate Bill 219, the Medical Psilocybin Act, signed April 2025 and effective June 20, 2025. Its qualifying conditions are major treatment-resistant depression, post-traumatic stress disorder, substance use disorders, end-of-life care, and other conditions the department approves.

“qualified patient” means a patient whose clinician has judged the patient to be a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition.SB 219, Section 3. The verb “has judged,” with “medically appropriate candidate,” denotes a clinical judgment layered on top of the diagnosis; diagnosis is necessary but not sufficient.

“clinician” means an approved health care provider licensed in New Mexico who holds a permit from the department to provide medical services to qualified patients.SB 219, Section 3. No controlled-substance number and no specific license type appears. Clinician qualifications are delegated to department rulemaking, where proposed rule 7.35.3 and the term “certifying clinician” live.

Scheduling. SB 219 did not move psilocybin to a lower schedule. It kept psilocybin and psilocin in Schedule I and added a medical-use carve-out: each entry now reads “except as provided otherwise in the Controlled Substances Act and the Medical Psilocybin Act,” and a new subsection provides that “the enumeration of psilocybin and psilocin in this schedule does not apply to their medical use as provided in the Medical Psilocybin Act.” The enacted title states the amendment is to “remove psilocybin and psilocin from the schedule for purposes of qualified medical treatment.”

Confirmed against the enacted text. Source: SB 219, Section 30-31-6 amendment.

New Mexico’s registration requirement turns on the act a person performs, not on a drug’s schedule number.

A person who manufactures, distributes or dispenses a controlled substance or who proposes to engage in the manufacture, distribution or dispensing of a controlled substance shall obtain a registration issued by the board in accordance with its regulations.NMSA 1978, Section 30-31-12(A). “The board” is the Board of Pharmacy. The trigger is the regulated act, not the schedule number.

Two facts set the frame. First, SB 219 uses “administering” and “recommending,” never “prescribe,” for psilocybin: it protects a clinician “administering… psilocybin” and one “recommending the program.” Second, psilocybin remains a Schedule I substance under federal law, which cannot be prescribed at all (21 U.S.C. Section 829), and an ordinary DEA registration cannot authorize handling it. A certifying clinician who holds a controlled-substance number holds it for their other practice; the number is not, and cannot be, exercised on the psilocybin.

The department’s stated reason and the statutory structure both belong on the record:

• The department’s stated purpose (July 9): licenses can diagnose some conditions (“a social worker can diagnose… PTSD and depression”), “but the main reason for the controlled substance number is because it is a treatment that is occurring with a medication… that is part of what ensures that there is that medical evaluation, that medical certification.”
• The structural reading: under Section 30-31-12, registration attaches to manufacturing, distributing, or dispensing, none of which the certifying clinician does to the psilocybin. So the number operates as a credential (a marker of prescriber-grade licensure), not as an authorization used on the drug. New Mexico’s medical-cannabis program has the same shape: providers “certify” or “recommend” rather than prescribe cannabis, and no controlled-substance number is used on the cannabis, because cannabis is federal Schedule I.

On July 9 the board sent this question back to the department to weigh alternatives. The department answered on July 17 that the requirement would stay, and the rule published on July 23 keeps it. Nothing in the published text changes the structural reading above: the number is still not exercised on the psilocybin.

Sources: NMSA 30-31-12; SB 219 Sections 3 and 5; 21 U.S.C. 829; July 9 transcript.

None of the three comparators gates access through a clinician who holds prescribing authority. Oregon and Colorado require no diagnosis or qualifying condition; Washington, D.C. medical cannabis lets adults self-certify. New Mexico’s proposed rule is the only one of the four that requires a clinician determination for entry.

Oregon (Measure 109 / ORS 475A). The Oregon Health Authority states: “To access psilocybin services, an individual must be 21 years of age or older” and “A prescription or medical referral is not required.” Safety contraindications can disqualify a client during preparation, but that is a disqualifier, not an affirmative diagnosis requirement.

Colorado (Proposition 122 / SB23-290). The implementing law contains no diagnosis, qualifying-condition, or physician-gatekeeper requirement; access is gated by age (21 and older), and the model runs through licensed facilitators and healing centers, not a prescriber. This finding rests partly on the law’s silence, corroborated by secondary legal analysis; rated medium confidence.

Washington, D.C. (medical cannabis). D.C. Code Section 7-1671.05 and D.C. Law 24-187 let adults 21 and older “self-certify… on a form provided by [the regulator] that they are utilizing cannabis for medical purposes,” replacing the prior requirement of a signed practitioner recommendation. Minors still require a recommendation; the permanent authority is D.C. Law 24-332 and the agency is now ABCA.

Verified. Sources: oregon.gov OHA; leg.colorado.gov SB23-290; code.dccouncil.gov.

Two alternatives were floated July 9: a consultation model and a behavioral-health-plus-telemedicine referral. The published rule took up part of this. 7.35.3.13 (A)(2), p. 8 lets a certifying clinician certify on a telemedicine evaluation, either against a six-month in-person lookback of their own, against records from a clinician who examined the patient in that window, or after a formal consult with that clinician. It did not take up a referral by a non-prescribing behavioral-health provider. The federal precedents below predate the rule and concern prescribing, which differs from certifying a patient for entry; they are context for how the same problem has been handled elsewhere, not endorsements.

• Covering-practitioner exception. The Ryan Haight Act generally requires one in-person evaluation before remotely prescribing a controlled substance, but permits a practitioner to evaluate a patient by telemedicine “at the request of a practitioner who… has conducted at least 1 in-person medical evaluation of the patient… within the previous 24 months.” It also exempts federal systems (Indian Health Service, Department of Veterans Affairs).
• Current flexibility. The DEA and HHS extended COVID-era flexibilities a fourth time, effective through December 31, 2026, five months after this page was last checked, letting a DEA-registered practitioner prescribe Schedule II–V controlled substances via telemedicine “without having conducted an in-person medical evaluation,” provided the prescription is for a legitimate medical purpose in the usual course of practice.
• Proposed permanent rule. The DEA has proposed a “special registration” that would let a patient receive prescribed controlled medications through telemedicine “without ever having an in-person medical evaluation,” covering Schedule III–V, with a narrower Schedule II track for specified board-certified specialties. Proposed, not final.

Extracted from primary sources; not put through the same fact-check as sections 1–5. Sources: APA Ryan Haight toolkit; Federal Register fourth extension; DEA rulemaking.

Board members raised liability for certifying a patient one will not treat on July 9. The general framework: a clinician’s formal decision that a patient foreseeably relies on can create a duty even without hands-on treatment, while informal advice is treated differently. The controlling illustrations are out-of-state case law, used here only to describe the framework, not as New Mexico authority.

The general rule: “Generally, a physician owes no duty to a patient without a physician-patient relationship. Without a physician-patient relationship, with no duty owed, there is no liability for ‘breach’ of that nonexistent duty.”

The exception that applies here: in Warren v. Dinter (Minnesota), the court held that “a duty arises between a physician and an identified third party when the physician provides medical advice and it is foreseeable that the third party will rely on that advice.” A physician who never examined the patient faced liability for a decision the patient relied on. The court distinguished a “formal medical decision” from informal “curbside” advice.

This describes why a certifying-clinician role can carry liability exposure. It does not quantify New Mexico exposure, and no New Mexico certifying-clinician liability authority was located. Whether a psilocybin certification is a “formal medical decision” of the kind that attaches a duty is an unlitigated question.

Illustrative, out-of-state and secondary. Sources: National Legal Research Group; Medical Economics on Warren v. Dinter (Minnesota).

The prescriber-eligible clinicians are the scarcest category and the most concentrated outside rural counties. The non-prescribing clinicians who can diagnose the qualifying conditions are far more available rurally.

• 27 of New Mexico’s 33 counties are designated, in whole or in part, as health professional shortage areas; almost all counties are a shortage area for mental health.
• Ten frontier counties, with 27,000 Medicaid managed-care enrollees combined, have no behavioral-health prescribers at all. Nineteen of the 33 counties have fewer than two licensed behavioral-health providers per 1,000 enrollees, all rural or frontier.
• Rural New Mexico had 40 psychiatrists (5.6 per 100,000) against 306 (21.6 per 100,000) in urban counties; multiple rural counties had zero. Rural social workers, who can diagnose but not prescribe, numbered 997 (140.0 per 100,000), about 25 times the rural psychiatrist rate.
• Only 29 percent of licensed behavioral-health providers are in rural and frontier counties, where nearly half of Medicaid managed-care enrollees live.

Extracted; not put through the same fact-check as sections 1–5. Sources: HHS OIG OEI-02-17-00490; University of Washington Rural Health Research Center (June 2025); Commonwealth Fund via NM In Depth.

The board did not endorse the requirement and sent it back to the department. No vote was taken. Ian Dunn will take it back to the department to reconsider.